

Perrigo Announces Launch Of Authorized Generic Version Of Taclonex® Ointment (Calcipotriene 0.005% / Betamethasone Dipropionate 0.064%)

DUBLIN, April 1, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex® Ointment (calcipotriene 0.005% / betamethasone dipropionate 0.064%).

Taclonex® Ointment (calcipotriene 0.005% / betamethasone dipropionate 0.064%) is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older. Brand sales were approximately \$110 million over the last 52-weeks according to Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This product was the result of the continued hard work and dedication of our Perrigo Rx team. This launch is another example of Perrigo's investment and commitment to making quality healthcare more affordable for consumers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products®" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Visit Perrigo on the Internet (<http://www.perrigo.com>).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2013, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable

securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company plc

For further information: Arthur J. Shannon, Vice President, Investor Relations and Global Communications, (269) 686-1709, E-mail: ajshannon@perrigo.com; Bradley Joseph, Director, Investor Relations and Global Communications, (269) 686-3373, E-mail: bradley.joseph@perrigo.com

<https://investor.perrigo.com/2014-04-01-Perrigo-Announces-Launch-Of-Authorized-Generic-Version-Of-Taclonex-Ointment-Calcipotriene-0-005-Betamethasone-Dipropionate-0-064>